Skip to main content
SpringerLink
Log in

Radiation Therapy in Diffuse Large B-Cell Lymphoma

  • Living reference work entry
  • First Online:
Radiation Oncology

  • 417 Accesses

Abstract

The treatment of Diffuse Large B-cell Lymphomas a multidisciplinary approach. The current chapter presents the staging and treatment options for patients with DLBCL. In addition to combined treatment concepts for early and advanced stages, up-to-date radiotherapeutic techniques, as well as dose concepts and target volumes for nodal and extranodal manifestations are introduced.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116:4283–90.

    Article  PubMed  Google Scholar 

  • Ahmad SS, Idris SF, Follows GA, Williams MV. Primary testicular lymphoma. Clin Oncol. 2012;24:358–65.

    Article  CAS  Google Scholar 

  • Cabanillas F, Shah B. Advances in diagnosis and management of diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17(12):783–96.

    Article  PubMed  Google Scholar 

  • Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the surveillance, epidemiology and end results database. Am J Hematol. 2014;89:310–4.

    Article  CAS  PubMed  Google Scholar 

  • Ceriani L, Martelli M, Zinzani PL, Ferreri AJ, Botto B, Stelitano C, Gotti M, Cabras MG, Rigacci L, Gargantini L, Merli F, Pinotti G, Mannina D, Luminari S, Stathis A, Russo E, Cavalli F, Giovanella L, Johnson PW, Zucca E. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126:950–6.

    Article  CAS  PubMed  Google Scholar 

  • Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123:486–93.

    Article  CAS  PubMed  Google Scholar 

  • Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  • Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015;121:1032–9.

    Article  CAS  PubMed  Google Scholar 

  • Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal b-cell lymphoma. N Engl J Med. 2013;368:1408–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Factors, International Non-Hodgkin's Lymphoma Prognostic. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–94.

    Article  Google Scholar 

  • Furlan C, Canzonieri V, Spina M, Michieli M, Ermacora A, Maestro R, Piccinin S, Bomben R, Dal Bo M, Trovo M, Gattei V, Tirelli U, Franchin G, Bulian P. Low-dose radiotherapy in diffuse large B-cell lymphoma. Hematol Oncol. 2016;35(4):472–9.

    Article  PubMed  Google Scholar 

  • Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270–7.

    Article  PubMed  Google Scholar 

  • Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Briere J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90.

    Article  PubMed  PubMed Central  Google Scholar 

  • Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, Bittenbring J, Hanel M, Wilhelm S, Schubert J, Schmitz N, Loffler M, Rube C, Pfreundschuh M. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112–8.

    Article  PubMed  Google Scholar 

  • Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rube C, Zwick C, Glass B, Schmitz N, Pfreundschuh M. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31:4115–22.

    Article  CAS  PubMed  Google Scholar 

  • Holzhäuser E, Berlin M, Wollschläger D, Heß G, Schmidberger H. Patterns of failure of diffuse large B-cell lymphoma (DLBCL) patients after involved site radiotherapy (ISRT) abstracts DEGRO 2017. Strahlenther Onkol. 2017;193:1–194.

    Article  Google Scholar 

  • Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmarajan K, Ng A, Ricardi U, Wirth A, Group International Lymphoma Radiation Oncology. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2014;89:49–58.

    Article  PubMed  Google Scholar 

  • Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O’Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684–8.

    Article  CAS  PubMed  Google Scholar 

  • Lamy T, Damaj G, Soubeyran P, Gyan E, Legouill S, Cartron G, Boubdallah K, Gressin R, Cornillon J, Banos A, Ledu K, Benchalal M, Moles M, Fleury J, Godmer P, Maisonneuve H, Deconninck E, Laribi K, Marolleau J, Tournilhac O, Deviller A, Fest T, Colombat P, Costes V, Bene M, Delwail V. R-CHOP +/− radiotherapy in non-bulky limited stage diffuse large B-cell lymphoma (DLBCL): final results of the prospective randomized phase III 02-03 trial from the LYSA/GOELAMS. Hematol Oncol. 2017;35:128–9.

    Article  Google Scholar 

  • Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86–92.

    Article  PubMed  Google Scholar 

  • Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017;113:318–27.

    Article  PubMed  Google Scholar 

  • Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89.

    Article  PubMed  Google Scholar 

  • Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjose S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadie M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr. 2014;2014:130–44.

    Article  PubMed  PubMed Central  Google Scholar 

  • Mulvihill DJ, McMichael K, Goyal S, Drachtman R, Weiss A, Khan AJ. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy. Radiother Oncol. 2014;112:279–83.

    Article  PubMed  Google Scholar 

  • Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hanel M, Witzens-Harig M, Mahlberg R, Rube C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood. 2014;124:720–8.

    Article  CAS  PubMed  Google Scholar 

  • Murray L, Sethugavalar B, Robertshaw H, Bayman E, Thomas E, Gilson D, Prestwich RJ. Involved node, site, field and residual volume radiotherapy for lymphoma: a comparison of organ at risk dosimetry and second malignancy risks. Clin Oncol (R Coll Radiol). 2015;27:401–10.

    Article  CAS  Google Scholar 

  • NCCN-Guidlines. 2017. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed Mar 2017.

  • Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Ferme C, Schiano JM, Coiffier B, Corront B, Farhat H, Fruchart C, Ghesquieres H, Macro M, Tilly H, Choufi B, Delarue R, Fitoussi O, Gabarre J, Haioun C, Jardin F. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4:e46–55.

    Article  PubMed  Google Scholar 

  • Pfreundschuh, M. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results if the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. J Clin Oncol. 2017; 37(suppl; abstr 6506).

    Google Scholar 

  • Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, Lopez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera international trial (MInT) group. Lancet Oncol. 2011;12:1013–22.

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, Group German High-Grade Non-Hodgkin Lymphoma Study. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–41.

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Christofyllakis K, Altmann B, Ziepert M, Haenel M, Viardot A, Neubauer A, Held G, Truemper L, Schmidt C, Kanz L, Hallek MJ, Schmitz N, Heintges T, Koelbel C, Schneider G, Ruebe C, Hellwig D, Poeschel V, Murawski N. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. J Clin Oncol. 2017;35:7506.

    Google Scholar 

  • Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28:4170–6.

    Article  PubMed  Google Scholar 

  • Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, Thieblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquieres H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858–67.

    Article  CAS  PubMed  Google Scholar 

  • RKI. Krebsgeschehen in Deutschland. 2016. http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebsgeschehen/Krebsgeschehen_node.html.

  • Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadie M, Simonetti A, Lutz JM, Berrino F, Haemacare Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.

    Article  CAS  PubMed  Google Scholar 

  • Specht L, Yahalom J. The concept and evolution of involved site radiation therapy for lymphoma. Int J Clin Oncol. 2015;20:849–54.

    Article  PubMed  Google Scholar 

  • Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A, Ilrog. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89:854–62.

    Article  PubMed  Google Scholar 

  • Spina M, Balzarotti M, Uziel L, Ferreri AJ, Fratino L, Magagnoli M, Talamini R, Giacalone A, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist. 2012;17:838–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, Andre M, Johnson PW, Pfreundschuh M, Ladetto M, Committee EG. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–25.

    Article  PubMed  Google Scholar 

  • Truemper, L. Haematologie im Wandel. 2015. https://www.kompetenznetz-leukaemie.de/content/e53457/e56787/e54977/e56782/13_Trmper_DSHNHL.pdf.

  • van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program. 2016;2016:323–30.

    PubMed  Google Scholar 

  • van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007–17.

    Article  PubMed  Google Scholar 

  • Vargo JA, Gill BS, Balasubramani GK, Beriwal S. Treatment selection and survival outcomes in early-stage diffuse large b-cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol. 2015;33:3710–7.

    Article  CAS  PubMed  Google Scholar 

  • Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A, Group International Lymphoma Radiation Oncology. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92:11–31.

    Article  PubMed  Google Scholar 

  • Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol. 2002;13(Suppl 1):79–83.

    Article  PubMed  Google Scholar 

  • Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany

    Chr. Berdel & Ch. Rübe

Authors
  1. Chr. Berdel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ch. Rübe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chr. Berdel .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University Hospital Mannheim, Mannheim, Germany

    Frederik Wenz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Berdel, C., Rübe, C. (2018). Radiation Therapy in Diffuse Large B-Cell Lymphoma. In: Wenz, F. (eds) Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-52619-5_20-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-52619-5_20-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-52619-5

  • Online ISBN: 978-3-319-52619-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation